World Pharma Today

  Dr. Oliver Okle is a product and service manager at Vetter The global CDMO market is projected to more than double from $161 billion in 2023 to $322.76 billion by 20331. This is only a portion of the rapid growth we’re witnessing in the broader pharmaceutical and biotech industry, driven by innovation and increased investment in research and development (R&D)2. This growth underscores the need for CDMOs to invest in advanced infrastructure, technologies, and process optimizations to stay ahead in the evolving market. In this interview, Dr. Oliver Okle, Product and Service Manager at Vetter, a globally operating CDMO, discusses the importance of trend scouting and how it helps outsourcing partners stay competitive. Dr. Okle, what are the key factors driving the rapid expansion of the pharmaceutical and biotech industries? In my experience, the primary drivers are innovation and increased R&D investment. The significant growth in the CDMO market, and the rise in R&D sp...

  Haleon today announces the appointment of Carl Haney as Chief Research & Development Officer. Carl will join Haleon on 1 August 2025. This appointment follows Franck Riot deciding to leave Haleon after six years in the business. Carl joins Haleon from the Estée Lauder Companies Inc. where he has spent 13 years as Executive Vice President, Global Innovation and Research and Development. Carl previously spent over 20 years at P&G across Home, Health and Beauty Care. Brian McNamara, Haleon’s Chief Executive Officer commented: “I am delighted to welcome Carl to Haleon. Carl is a world-renowned leader in R&D, with significant experience of driving transformative innovation within global consumer businesses. He will be an excellent addition to our executive team as we look to build on the strong foundations we have built in recent years and unlock Haleon’s significant potential through our new Win as One strategy. “I want to take this opportunity to thank Franck for his sig...

  RHEINFELDEN, Switzerland – Life Science Newswire – Tillotts Pharma AG (“Tillotts”) proudly marks its 15th anniversary as a member of the Japanese Zeria Group, celebrating a period of exceptional growth and valuable collaboration together. The milestone was commemorated in December 2024 with Tillotts’ CEO, Thomas A. Tóth von Kiskér, and members of the leadership team visiting Zeria. During this special occasion, Mr. Sachiaki Ibe, Chairman of the Board of Directors and CEO of Zeria Pharmaceutical Co., Ltd., presented Mr. Tóth a symbolic piece of Japanese art featuring Mount Fuji as a gift to honor Zeria’s appreciation for Tillotts’ remarkable accomplishments since the acquisition. Over the past 15 years, Tillotts has consistently achieved strong double-digit growth and broadened its portfolio while leveraging the trust and support of the Zeria Group. Tillotts’ remarkable success and progress is largely due to the exceptional dedication of its employees, who constantly strive to unl...